Cardio.Flux Service

Our Cardio.Flux Service provides high-throughput (HT) cardiac safety assessment by monitoring Ca2+ transients in healthy* cardiomyocytes. Direct, acute drug effects on both electrophysiology and contractility of cardiomyocytes can be detected with the HT Cardio.Flux Service and will help expedite decision making at early stages of preclinical drug development.

This service is based on executing fluorescent based assays that measure changes in intracellular calcium handling using the FLIPR® Tetra system (Molecular Devices). Since calcium is the interdependent regulator between cardiomyocyte electrophysiology and contraction, compounds affecting ion channels can (in)directly affect intracellular calcium transients. The analysis of fluorescent intracellular calcium transients is excellent for identifying acute compound effects on cardiomyocyte electrophysiology and contractility at high-throughput. We offer this service in collaboration with Pivot Park Screening Centre (PPSC), allowing ultra HT (uHT) screenings using automation and miniaturization.

*Are you interested in disease models or patient-specific Pluricyte® Cardiomyocytes for your cardiovascular drug discovery studies? Please contact us to discuss the possibilities.


Service specifications

Cell type

iPSC derived cardiomyocytes



Service type

Calcium-flux functional analysis


96 Well plate

Assay window

30 Minute compound exposure

Compound concentrations*

0.1, 1, 10 µM in medium + 0.1% DMSO (in triplicates)

Positive controls

L-type Ca2+ channel blocker: Nitrendipine 100 nM

hERG blocker: Dofetilide 30 nM

Vehicle control

0.1% DMSO


Peak frequency (beat rate), peak amplitude, peak width diameter and proarrhythmic events


3 Weeks (for up to 9 compounds)


A study protocol will be sent to initiate the study. Results are sent as draft and final study report.

*Suggested concentrations, to be agreed with client